Who Paid My Doc
Imcivree
Drug Genetic Disease
NDC 72829-010-01
General payments
$550,400
Research payments
$13,745,914
Through program year 2025, $550,400 in general payments and $13,745,914 in research payments were reported against Imcivree (Genetic Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $73,684 | 1,510 |
| 2024 | General | $74,828 | 878 |
| 2024 | Research | $27,871 | 7 |
| 2023 | General | $168,829 | 1,559 |
| 2023 | Research | $5,945,596 | 1,663 |
| 2022 | General | $232,854 | 362 |
| 2022 | Research | $4,821,010 | 913 |
| 2021 | General | $204 | 3 |
| 2021 | Research | $2,951,438 | 223 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 60 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,312 general · 2,806 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.